Overexpression of HER2 usually results in malignant transformation of cells, accounting for ~25% of all breast cancers (clinical serum cut-off 15 ng/mL) and it is always associated with more aggressive tumor phenotypes. The gene discussed is ERBB2; the disease is neoplasm.